Editas Medicine (EDIT) Competitors

$2.53 -0.09 (-3.44%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$2.55 +0.02 (+0.95%)

As of 07:13 AM Eastern

EDIT vs. BEAM, CRSP, NTLA, CALT, and COLL

Should you buy Editas Medicine stock or one of its competitors? MarketBeat compares Editas Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Calliditas Therapeutics AB (publ) (CALT), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.

How does Editas Medicine compare to Beam Therapeutics?

Editas Medicine (NASDAQ:EDIT) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Beam Therapeutics had 17 more articles in the media than Editas Medicine. MarketBeat recorded 21 mentions for Beam Therapeutics and 4 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.66 beat Beam Therapeutics' score of -0.26 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.11	-$160.06M	-$1.23	N/A
Beam Therapeutics	$139.74M	19.74	-$79.99M	-$0.68	N/A

Editas Medicine has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market.

Beam Therapeutics has a net margin of -39.66% compared to Editas Medicine's net margin of -281.59%. Beam Therapeutics' return on equity of -29.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Editas Medicine presently has a consensus target price of $5.40, indicating a potential upside of 113.44%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 74.69%. Given Editas Medicine's higher probable upside, analysts clearly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Beam Therapeutics beats Editas Medicine on 14 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Editas Medicine has a net margin of -281.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Editas Medicine	-281.59%	-677.39%	-58.25%

In the previous week, CRISPR Therapeutics and CRISPR Therapeutics both had 4 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.79 beat Editas Medicine's score of 0.66 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics presently has a consensus price target of $65.47, suggesting a potential upside of 34.82%. Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 113.44%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,334.36	-$581.60M	-$6.22	N/A
Editas Medicine	$40.52M	6.11	-$160.06M	-$1.23	N/A

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Editas Medicine beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Intellia Therapeutics had 21 more articles in the media than Editas Medicine. MarketBeat recorded 25 mentions for Intellia Therapeutics and 4 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.66 beat Intellia Therapeutics' score of 0.37 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has a net margin of -281.59% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Editas Medicine	-281.59%	-677.39%	-58.25%

Intellia Therapeutics currently has a consensus target price of $20.25, indicating a potential upside of 59.57%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 113.44%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Intellia Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Editas Medicine has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	26.20	-$412.69M	-$3.54	N/A
Editas Medicine	$40.52M	6.11	-$160.06M	-$1.23	N/A

Summary

Intellia Therapeutics and Editas Medicine tied by winning 8 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Calliditas Therapeutics AB (publ)?

Editas Medicine (NASDAQ:EDIT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Editas Medicine had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Editas Medicine and 0 mentions for Calliditas Therapeutics AB (publ). Editas Medicine's average media sentiment score of 0.66 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Editas Medicine	Positive
Calliditas Therapeutics AB (publ)	Neutral

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Editas Medicine's net margin of -281.59%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Editas Medicine. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.11	-$160.06M	-$1.23	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Editas Medicine currently has a consensus target price of $5.40, suggesting a potential upside of 113.44%. Given Editas Medicine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Editas Medicine is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 3.1% of Editas Medicine shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Editas Medicine has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Summary

Editas Medicine beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Collegium Pharmaceutical?

Editas Medicine (NASDAQ:EDIT) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

71.9% of Editas Medicine shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Editas Medicine presently has a consensus price target of $5.40, suggesting a potential upside of 113.44%. Collegium Pharmaceutical has a consensus price target of $57.50, suggesting a potential upside of 70.88%. Given Editas Medicine's higher possible upside, equities research analysts plainly believe Editas Medicine is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Editas Medicine. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 4 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.66 beat Collegium Pharmaceutical's score of 0.42 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Collegium Pharmaceutical has a net margin of 9.41% compared to Editas Medicine's net margin of -281.59%. Collegium Pharmaceutical's return on equity of 95.18% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Collegium Pharmaceutical has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.11	-$160.06M	-$1.23	N/A
Collegium Pharmaceutical	$780.57M	1.40	$62.87M	$2.04	16.50

Editas Medicine has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDIT vs. The Competition

Export

Metric	Editas Medicine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$256.51M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-2.06	18.13	20.64	25.23
Price / Sales	6.11	289.87	554.85	79.36
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	9.04	6.57	9.66	6.63
Net Income	-$160.06M	$24.35M	$3.56B	$335.59M
7 Day Performance	-13.65%	-2.53%	-1.65%	-1.20%
1 Month Performance	-27.51%	-3.55%	-2.60%	-1.16%
1 Year Performance	69.80%	53.51%	30.07%	28.10%

Editas Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDIT Editas Medicine	3.4607 of 5 stars	$2.53 -3.4%	$5.40 +113.4%	+67.5%	$256.51M	$40.52M	N/A	230
BEAM Beam Therapeutics	3.5365 of 5 stars	$31.58 -0.5%	$47.17 +49.4%	+49.9%	$3.27B	$139.74M	N/A	510
CRSP CRISPR Therapeutics	3.2434 of 5 stars	$52.83 -2.2%	$66.06 +25.0%	+25.3%	$5.21B	$3.51M	N/A	460
NTLA Intellia Therapeutics	2.839 of 5 stars	$13.99 -3.0%	$20.36 +45.6%	+49.3%	$1.74B	$67.67M	N/A	600	Analyst Downgrade
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDIT) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, CALT, and COLL

How does Editas Medicine compare to Beam Therapeutics?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Summary

How does Editas Medicine compare to Calliditas Therapeutics AB (publ)?

Summary

How does Editas Medicine compare to Collegium Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, CALT, and COLL

How does Editas Medicine compare to Beam Therapeutics?

Does the media refer more to EDIT or BEAM?

Do insiders & institutionals believe in EDIT or BEAM?

Which has better valuation and earnings, EDIT or BEAM?

Which has more volatility & risk, EDIT or BEAM?

Is EDIT or BEAM more profitable?

Do analysts rate EDIT or BEAM?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Is CRSP or EDIT more profitable?

Does the media prefer CRSP or EDIT?

Do analysts recommend CRSP or EDIT?

Which has more volatility and risk, CRSP or EDIT?

Which has higher valuation and earnings, CRSP or EDIT?

Do insiders and institutionals hold more shares of CRSP or EDIT?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Do institutionals & insiders believe in NTLA or EDIT?

Does the media prefer NTLA or EDIT?

Is NTLA or EDIT more profitable?

Do analysts rate NTLA or EDIT?

Which has more risk & volatility, NTLA or EDIT?

Which has stronger earnings and valuation, NTLA or EDIT?

Summary

How does Editas Medicine compare to Calliditas Therapeutics AB (publ)?

Does the media refer more to EDIT or CALT?

Is EDIT or CALT more profitable?

Which has stronger valuation & earnings, EDIT or CALT?

Do analysts rate EDIT or CALT?

Do institutionals and insiders have more ownership in EDIT or CALT?

Which has more volatility and risk, EDIT or CALT?

Summary

How does Editas Medicine compare to Collegium Pharmaceutical?

Do institutionals & insiders have more ownership in EDIT or COLL?

Do analysts rate EDIT or COLL?

Does the media refer more to EDIT or COLL?

Is EDIT or COLL more profitable?

Which has better earnings and valuation, EDIT or COLL?

Which has more risk & volatility, EDIT or COLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools